FDA Approves NGS-Based Companion Diagnostic for First Targeted Therapy in Patients with Grade 2 IDH-Mutant Glioma
Thermo Fisher Scientific, the world leader in serving science, has received approval from the U.S. Food and Drug Administration (FDA) for its Ion Torrent™ Oncomine™ Dx Target Test as a companion diagnostic (CDx) to identify patients eligible for treatment with Servier Pharmaceuticals,…